# Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

> **NCT00306566** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cytos Biotechnology AG**

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** CYT004-MelQbG10

## Key facts

- **NCT ID:** NCT00306566
- **Lead sponsor:** Cytos Biotechnology AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2007-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00306566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00306566, "Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00306566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*